Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer

Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer

Tamoxifen is the drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women in the reproductive period.  The metabolic activity of tamoxifen is determined by the activity of the enzyme CYP2D6, encoded by the gene of the same name: under  the action of the enzyme, tamox...

Full description

Bibliographic Details
Main Authors: L. N. Lyubchenko, M. G. Filippova, T. A. Shendrikova, L. G. Zhukova, N. I. Mekhtieva, O. V. Krokhina, S. M. Portnoy
Format: Article
Language:Russian
Published: ABV-press 2017-10-01
Series:Успехи молекулярной онкологии
Subjects:
tamoxifen
pharmacogenetics testing
cyp2d6 gene
hormonotherapy
breast cancer
Online Access:https://umo.abvpress.ru/jour/article/view/102

Similar Items

Similar Items